Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T11634 |
IL-15-IN-1
|
IL Receptor; Interleukin | Immunology/Inflammation |
IL-15-IN-1是一种 IL-15依赖性细胞的选择性抑制剂(IC50:0.8 μM)。 | |||
T77034 |
Inbakicept
N-803 |
||
Inbakicept (ALT-803) 是一种 IL-15超激动剂,由 IL-15突变体和 IL-15Rα-Fc 融合体组成。Inbakicept 可放大抗 CD20单抗介导的 NK 细胞反应和抗体依赖性细胞毒性 (ADCC)。INbakicept 也增加 NK 细胞的脱粒或 IFNγ 的产生。 | |||
T77156 | Depemokimab | ||
Depemokimab (GSK-3511294) 是一种长效的抗IL-15单克隆抗体。Depemokimab 可用于哮喘研究。 | |||
T73014 | NLRP3-IN-15 | ||
NLRP3-IN-15 是一种有效的、选择性的 NLRP3炎症小体抑制剂 (KD: 5.87 μM)。NLRP3-IN-15 抑制 IL-1β 释放,IC50为 0.131 μM。NLRP3-IN-15可用于炎症研究。 | |||
T79362 |
COX-2/15-LOX-IN-4
|
Lipoxygenase | Metabolism |
COX-2/15-LOX-IN-4(compound 5i)是一种针对COX-2和15-LOX的双重抑制剂,其IC50值分别为0.075 μM和1.97 μM。该化合物能有效地阻止LPS诱发的细胞内促炎细胞因子(IL-6, ROS)的产生,表现出明确的抗炎活性。 | |||
T79361 |
COX-2/15-LOX-IN-3
|
Lipoxygenase | Metabolism |
COX-2/15-LOX-IN-3 (compound 5k) 为COX-2/15-LOX的一种双重抑制剂,具有分别为0.075 μM和1.97 μM的IC50值。该化合物能显著抑制LPS诱导的细胞产生促炎细胞因子(IL-6, ROS和NO),表明其具备显著的抗炎活性。 | |||
T79385 |
PDE1-IN-5
|
||
PDE1-IN-5 (Compound 10c) 是一种PDE1C选择性抑制剂,IC50为15 nM。该化合物显示出抗炎活性,能够抑制LPS诱导的iNOS、TNF-α、IL-1α、IL-1β和IL-6表达。在DSS诱导的结肠炎小鼠模型中,PDE1-IN-5对抗炎性肠病(IBD)表现出治疗潜力,并可用于IBD相关研究。 | |||
T73330 |
JAK-IN-24
|
||
JAK-IN-24 是一种 JAK 抑制剂,在 4 μM 或 1 mM ATP 存在时,IC50分别为 0.534 和 24 nM。JAK-IN-24 还抑制 PBMCIL-15诱导的 STAT5磷酸化,IC50为 86.171 nM。 | |||
T60560 | Anti-inflammatory agent 15 | ||
Anti-inflammatory agent 15 (化合物 29) 是有效的抗结核分枝杆菌剂,可用于结核病(TB)的研究。Anti-inflammatory agent 15 抑制 Mtb H37Rv 和 M299生长,MIC50分别为 2.3 和 7.8 μM。Anti-inflammatory agent 15也是一种抗炎剂, 通过抑制 iNOS 的表达来抑制 NO,同时也抑制 TNF-α 和 IL-1β 的产生。 | |||
T75096 | STING agonist-28 | ||
STINGagonist-28 (CF510) 是一种非核苷酸小分子STING 激动剂。STINGagonist-23 激活STING,增加STING、TBK1和IRF3的磷酸化。STINGagonist-23 可促进肿瘤细胞中IFN-β、IL-6、CXCL-10、TNF-α、ISG-15和CCL-5的水平。STINGagonist-23 表现出抗SARS-CoV 系列的活性。 | |||
T75094 | STING agonist-26 | ||
STINGagonist-26 (CF508) 是一种非核苷酸小分子STING 激动剂。STINGagonist-23 激活STING,增加STING、TBK1和IRF3的磷酸化。STINGagonist-23 可促进肿瘤细胞中IFN-β、IL-6、CXCL-10、TNF-α、ISG-15和CCL-5的水平。STINGagonist-23 表现出抗SARS-CoV 系列的活性。 | |||
T75092 | STING agonist-24 | ||
STINGagonist-24 (CF504) 是一种非核苷酸小分子STING 激动剂。STINGagonist-23 激活STING,增加STING、TBK1和IRF3的磷酸化。STINGagonist-23 可促进肿瘤细胞中IFN-β、IL-6、CXCL-10、TNF-α、ISG-15和CCL-5的水平。STINGagonist-23 表现出抗SARS-CoV 系列的活性。 | |||
T75093 | STING agonist-25 | ||
STINGagonist-25 (CF505) 是一种非核苷酸小分子 STING 激动剂。STINGagonist-23 激活 STING,增加 STING、TBK1和 IRF3的磷酸化。STINGagonist-23 可促进肿瘤细胞中IFN-β、IL-6、CXCL-10、TNF-α、ISG-15和CCL-5的水平。STINGagonist-23 表现出抗SARS-CoV 系列的活性。 | |||
T83670 |
F1 TFA
Tat-IKIP (46-60),Tat-Inhibitor of NF-κB Kinase-interacting Peptide |
||
F1是一种抗炎肽,由HIV-1 Tat蛋白质转导域与对应于抑制因子NF-κB激酶-相互作用肽(IKIP)46-60残基的15氨基酸肽链接而成。在5 µM浓度下,F1抑制了小鼠腹腔巨噬细胞中LPS诱导的IκB激酶α(IKKα)和IKKβ的磷酸化以及NF-κB(p65)的核内转移。在体内,F1(5 mg/kg)降低了LPS诱导的脓毒症小鼠模型中IL-6、TNF-α和IL-1β的血清水平,并增加了生存率。 | |||
T71884 |
ß-Carboline-1-carboxylic acid
|
||
β-Carboline-1-carboxylic acid is an alkaloid that has been found in P. quassioides and has diverse biological activities. It reduces LPS-induced increases in MCP-1, TNF-α, IL-6, and IL-1β levels in RAW 264.7 cells when used at a concentration of 15 µg/ml and inhibits the epithelial-to-mesenchymal transition (EMT) induced by TGF-β1 in A549 cells. β-Carboline-1-carboxylic acid induces cytotoxicity in CT26.WT, K562, and SGC-7901 cells (IC50s = 14.96, 22.11, and 19.7 µg/ml, respectively) but not Hep... | |||
T82189 |
HMGB1-IN-2
|
||
HMGB1-IN-2 (compound 15) 是一种针对高度保守的核蛋白 HMGB1 的抑制剂,其在 RAW264.7 细胞中展现出 NO 抑制活性,IC50 为 20.2 μM。 HMGB1-IN-2 (30 μM) 能够减少 IL-1β、TNF-α、caspase-1 p20 的表达,并抑制 NF-κB p65 的磷酸化作用,显示出抗凋亡特性。在脓毒症急性肾损伤模型的小鼠中,HMGB1-IN-2(15 mg/kg;腹腔注射)可有效减轻肾脏伤害。此外,HMGB1-IN-2 对 Huh7 细胞和 A549 细胞的 IC50 分别为 77.0 μM 和 82.0 μM。 | |||
T75091 | STING agonist-23 | ||
STINGagonist-23 (CF502) 是一种非核苷酸小分子 STING 激动剂。STINGagonist-23 激活 STING,增加 STING、TBK1和 IRF3的磷酸化。STINGagonist-23 可促进肿瘤细胞中 IFN-β、IL-6、CXCL-10、TNF-α、ISG-15和 CCL-5的水平。STINGagonist-23 表现出抗 SARS-CoV 系列的活性。 | |||
T36629 | Givinostat | ||
Givinostat (ITF-2357) is a HDAC inhibitor with an IC50 of 198 and 157 nM for HDAC1 and HDAC3, respectively. Givinostat (ITF2357) suppresses total LPS-induced IL-1β production robustly compared with the reduction by ITF3056. At 25, 50, and 100 nM, Givinostat reduced IL-1β secretion more than 70%. Givinostat (ITF-2357) suppresses the production of IL-6 in PBMCs stimulated with TLR agonists as well as the combination of IL-12 plus IL-18. IL-6 secretion decreases to 50% at 50 nM Givinostat, but at 1... | |||
T38309 |
LL-37 amide (trifluoroacetate salt)
|
||
LL-37 is a cationic and α-helical antimicrobial peptide expressed in human bone marrow, testis, granulocytes, and gingival epithelium and is upregulated in psoriatic lesions. It inhibits growth of Gram-positive E. coli D21 and Gram-negative B. megatarium in a concentration-dependent manner and LL-37 expression is induced in A549 epithelial cells, alveolar macrophages, neutrophils, and monocyte-derived macrophages following M. tuberculosis infection. LL-37 binds sheep erythrocytes coated with S. ... | |||
T36486 |
Benpyrine
|
||
Benpyrine is a highly specific and orally active TNF-α inhibitor with a KD value of 82.1 μM. Benpyrine tightly binds to TNF-α and blocks its interaction with TNFR1, with an IC50 value of 0.109 μM. Benpyrine has the potential for TNF-α mediated inflammatory and autoimmune disease research[1]. Benpyrine (5-20 μM; 14 hours; RAW264.7 cells) pretreatment results in a dose-dependent decrease in the phosphorylation of IκBα in RAW264.7 cells (stimulated with 10 ng/mL TNF-α or 1 μg/mL LPS). Benpyrine abo... |